Comparison of Concomitant Mesalamine and Immunomodulator Therapy and Immunomodulator Monotherapy for Crohn’s Disease

Figure 1

Cumulative probabilities of patients requiring steroids (a) and biological agent treatment (b).

(a)

(b)